Emkay Global Financial Services has come out with its report on banking sector. Sector bias towards banks with robust profitability over FY16-17e, says research report.
Posts tagged MC
Core earnings- a meaningful driver of banks’ PBV: Emkay (18-09-2015)
Warning: EM bounce will be short-lived (18-09-2015)
The US central bank on Thursday held off on raising rates amid heightened “uncertainties abroad,” including China’s economic weakness as well as sluggish inflation at home. A rate hike would have ended a nearly 7-year-old zero interest rate policy.
Greece heads to the polls (again): Why it matters (18-09-2015)
With the latest general election results due on Sunday, and polls suggesting a tight race to govern the struggling euro zone economy, CNBC looks at why this could be an important vote for the country – and the single currency.
Sell Gujarat Gas; target of Rs 500: Emkay (18-09-2015)
Brokerage house Emkay Global Financial Services is bearish on Gujarat Gas and has recommended sell rating on the stock with a target price of Rs 500 in its research report dated September 14, 2015.
Buy Raymond; target of Rs 755: Finquest (18-09-2015)
Finquest is bullish on Raymond and has recommended buy rating on the stock with a target price of Rs 755 in its research report dated September 16, 2015.
Buy Arvind; target of Rs 330: ICICI Direct (18-09-2015)
ICICI Direct is bullish on Arvind and has recommended buy rating on the stock with a target price of Rs 330 in its research report dated September 18, 2015.
Buy Firstsource Solutions; target of Rs 38: Sharekhan (18-09-2015)
Sharekhan is bullish on Firstsource Solutions and has recommended buy rating on the stock with a target price of Rs 38 in its research report dated September 16, 2015.
Emkay’s research report on Torrent Pharma (18-09-2015)
Emkay has recommended rating of accumulate on Torrent Pharma with a target price of Rs 1638 in its research report dated September 16, 2015.
Jubilant Life gets USFDA nod for anti-migraine tablets (18-09-2015)
The company has received nod from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for zolmitriptan orally disintegrating tablets in strengths of 2.5 mg and 5 mg, Jubilant Life Sciences said in a regulatory filing.
Jubilant Life gets USFDA nod for anti-migraine tablets (18-09-2015)
The company has received nod from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for zolmitriptan orally disintegrating tablets in strengths of 2.5 mg and 5 mg, Jubilant Life Sciences said in a regulatory filing.